News
LCTX
0.9300
-5.10%
-0.0500
Weekly Report: what happened at LCTX last week (0520-0524)?
Weekly Report · 3d ago
Weekly Report: what happened at LCTX last week (0513-0517)?
Weekly Report · 05/20 11:20
Buy Rating on Lineage Therapeutics Backed by Roche Collaboration and Solid Financials
TipRanks · 05/14 08:46
Weekly Report: what happened at LCTX last week (0506-0510)?
Weekly Report · 05/13 11:32
Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)
Oncolytics Biotech (ONCY) and Lineage Therap (LCTX) have 2 analysts maintaining Buy ratings on the Healthcare sector. Maxim Group's Jason McCarthy and Robert W. Baird's Michael Okunewitch both have bullish sentiments on the stocks.
TipRanks · 05/11 16:00
Lineage Cell Therapeutics, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 05/10 13:07
Analysts’ Top Healthcare Picks: Caribou Biosciences (CRBU), Lineage Therap (LCTX)
TipRanks · 05/10 10:30
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024
Lineage Cell Therapeutics reported earnings per share of -4 cents for the first quarter of 2024. The company reported revenue of $1.44 million. This was 6.18% better than the analyst estimate for revenue of -5%. The company just reported results.
Investorplace · 05/10 01:58
Lineage Cell Therapeutics Q1 2024 GAAP EPS $(0.04), Inline, Sales $1.444M Beat $1.359M Estimate
Lineage Cell Therapeutics reports quarterly losses of $0.04 per share. The company reported quarterly sales of $1.444 million which beat the analyst consensus estimate by 6.22%. The company also reported a 33.33 percent decrease in sales from the same period last year.
Benzinga · 05/09 21:03
Lineage Cell Therapeutics GAAP EPS of -$0.04 in-line, revenue of $1.44M beats by $0.08M
Seeking Alpha · 05/09 20:22
*Lineage Cell Therapeutics 1Q Rev $1.44M >LCTX
Dow Jones · 05/09 20:03
*Lineage Cell Therapeutics 1Q Loss/Shr 4c >LCTX
Dow Jones · 05/09 20:03
Press Release: Lineage Cell Therapeutics Reports -2-
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies to address unmet medical needs. The company's neuroscience focused pipeline includes a cell therapy for the treatment of vision loss. Lineage's forward-looking statements involve risks, uncertainties and other factors.
Dow Jones · 05/09 20:01
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: Unity Software, Main Street Capital Corporation and Wheaton Precious Metals Corp. Other earnings slated for release after Thursday's close include Unity Software and Blink Charging Co. For the full earnings season calendar, click here.
Seeking Alpha · 05/08 21:35
Buy Rating for Lineage Cell Therapeutics as OpRegen Shows Durable Benefits for GA Patients
TipRanks · 05/08 04:35
Maintained Buy Rating for Lineage Cell Therapeutics on Robust Clinical Trial Results and Strong Partnership with Roche
TipRanks · 05/06 20:55
Lineage Cell Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 05/06 14:50
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga · 05/06 14:40
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Axonics Modulation Technologies (AXNX) and Artivion (AORT)
TipRanks · 05/06 13:00
Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
Lineage Cell Therapeutics: OpRegen may counteract RPE cell dysfunction and cell loss in patients with geographic atrophy secondary to age-related macular degeneration. The results were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit. The company is developing a cell therapy for the treatment of dry AMD.
Benzinga · 05/06 12:04
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.